Compare · CDNA vs ELV
CDNA vs ELV
Side-by-side comparison of CareDx Inc. (CDNA) and Elevance Health Inc. (ELV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CDNA and ELV operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $85.74B, about 66.3x CDNA ($1.29B).
- Over the past year, CDNA is up 32.1% and ELV is up 6.1% - CDNA leads by 26.0 points.
- CDNA has been more active in the news (14 items in the past 4 weeks vs 8 for ELV).
- ELV has more recent analyst coverage (23 ratings vs 18 for CDNA).
- Company
- CareDx Inc.
- Elevance Health Inc.
- Price
- $25.04+0.04%
- $394.91+0.01%
- Market cap
- $1.29B
- $85.74B
- 1M return
- +16.19%
- +1.37%
- 1Y return
- +32.07%
- +6.06%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 14
- 8
- Recent ratings
- 18
- 23
CareDx Inc.
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision in HLA typing at a low to intermediate resolution for samples that uses real-time polymerase chain reaction methodology; and TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors. CareDx, Inc. has a license agreement with Illumina, Inc. for the distribution, development and commercialization rights to NGS products and technologies; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Latest CDNA
- President and CEO Hanna John Walter Jr sold $424,877 worth of shares (17,683 units at $24.03) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 631,959 units (SEC Form 4)
- Director Valantine Hannah was granted 9,795 shares and sold $279,728 worth of shares (12,103 units at $23.11) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 36,686 units (SEC Form 4)
- Director Cournoyer Christine was granted 9,795 shares, increasing direct ownership by 20% to 58,943 units (SEC Form 4)
- Director Riggsbee Richard Bryan was granted 9,795 shares, increasing direct ownership by 33% to 39,312 units (SEC Form 4)
- Director Cohen Fred E was granted 9,795 shares, increasing direct ownership by 6% to 165,060 units (SEC Form 4)
- Director Gunasekaran Suresh was granted 9,795 shares, increasing direct ownership by 36% to 37,248 units (SEC Form 4)
- Director Bickerstaff George was granted 9,795 shares, increasing direct ownership by 7% to 154,061 units (SEC Form 4)
- Director Goldberg Michael was granted 9,795 shares, increasing direct ownership by 5% to 195,737 units (SEC Form 4)
- CareDx Announces Second KOAR Analysis Published in the Journal of the American Society of Nephrology
- President and CEO Hanna John Walter Jr sold $528,443 worth of shares (21,998 units at $24.02) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 649,642 units (SEC Form 4)
Latest ELV
- Elevance Health Makes Clinical Review Faster, More Connected with Health OS
- SEC Form 11-K filed by Elevance Health Inc.
- SEC Form 11-K filed by Elevance Health Inc.
- Elevance Health Announces $640 Million Investment in Affordable Housing Over the Past Five Years, Surpassing $1 Billion in Total Commitment Nationwide
- CAO & Controller Penczek Ronald W sold $148,766 worth of shares (369 units at $403.16), decreasing direct ownership by 9% to 3,740 units (SEC Form 4)
- Elevance Health Makes Chronic Care Easier to Navigate With Connected, Personalized Support
- Director Dixon Robert L Jr sold $60,667 worth of shares (151 units at $401.77), decreasing direct ownership by 1% to 10,734 units (SEC Form 4)
- Elevance Health Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Elevance Health Expands Access to Digital Tools, Helping Bridge the Healthcare Digital Divide
- CAO & Controller Penczek Ronald W exercised 1,531 shares at a strike of $294.30 and sold $617,192 worth of shares (1,531 units at $403.13) (SEC Form 4)